Publisher： Bentham Science Publishers
E-ISSN： 1875-533x|7|6|663-672
ISSN： 0929-8673
Source： Current Medicinal Chemistry, Vol.7, Iss.6, 2000-06, pp. : 663-672
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Rational drug design utilizing available X-ray crystal structures of sialic acid analogues bound to the active site of influenza virus neuraminidase has led to the discovery of a series of potent carbocyclic influenza neuraminidase inhibitors. From this series, GS 4104 (oseltamivir, TAMIFLU) has emerged as a promising antiviral for the treatment and prophylaxis of human influenza infection. This article will summarize the design, discovery, and development of oseltamivir as an oral therapeutic to treat influenza infection.
Related content
Access to resources
Recommend
Neuraminidase inhibitor RWJ 270201 prepares to compete in influenza market
Inpharma, Vol. 1, Iss. 1260, 2000-01 ,pp. :